Merck & Co. announced that the Phase III KEYNOTE-040 study of Keytruda (pembrolizumab) in previously treated patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) failed to meet its pre-specified primary endpoint of overall s